ANGLE technology used in cutting-edge research featured in science journal Nature

Parstortix was central to the analysis carried out by a team at the University of Basel, in Switzerland

cancer cells
Scientists have come closer to understanding why cancer spreads in the way it does

ANGLE PLC (LON:AGL), the med-tech firm at the forefront of cancer research, said its liquid biopsy system has been used in research featured in the prestigious science journal Nature.

Parstortix was central to the analysis carried out by a team at the University of Basel, in Switzerland, which highlighted the role of immune cells assigned to protect the body from the disease in actually promoting the spread of cancer - a process called metastasis.

READ: ANGLE on track to complete key Parsortix study in current quarter

The research published in Nature identified a subset of circulating tumour cell clusters using ANGLE's technology that was demonstrated to be associated with greatly increased metastatic ability.

Understanding the role of the patient’s own immune system in aiding cancer spread opens the potential for the development of new therapies that impede the process.

"Research into CTC clusters using the Parsortix system has the potential to change the way that cancer is treated,” said ANGLE founder and chief executive Andrew Newland.

“The publication of the University of Basel's research in Nature on CTC-neutrophil clusters, following the previous publication in Cell, is a tremendous achievement for Basel, one of ANGLE's leading customers.

“We are delighted that the harvesting of CTC clusters, using the Parsortix system, is a key element in the drive to block the process of cancer metastasis that is responsible for over 90% of deaths from cancer."

Quick facts: ANGLE PLC

Price: £0.71

Market: AIM
Market Cap: £122.66 m


ANGLE PLC - Proactive One2One investor forum May 2019

ANGLE PLC’s (LON:AGL) chief executive Andrew Newland presents at the Proactive Investors One2One investor forum May 2019. For more information visit www.angleplc.com

on 24/5/19

2 min read